Contraceptive Efficacy, Tolerance and Acceptability of a Benzalkonium Chloride Spermicide Cream In Women Aged Over 40 Years of Age

Contraception Clinical Trial

— BZK40+  

Official title:

Contraceptive Efficacy, Tolerance and Acceptability of a Benzalkonium Chloride Spermicide Cream In Women Aged Over 40 Years of Age

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03102450
• Other study ID #: PHX 401-14
• Status: Completed
• Phase: Phase 4
• Start date: December 26, 2017
• Est. completion date: October 17, 2019

Study information

• Verified date: February 2020
• Source: Laboratoire Innotech International
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In spite of many advantages of spermicides, there is no contraceptive efficacy study conducted with any spermicide in women aged over 40 years. That is why the aim of this study is to evaluate contraceptive efficacy, tolerance and acceptability of a spermicide with benzalkonium chloride (Pharmatex® cream) in women aged over 40 years.

Description:

Not all contraceptive methods are appropriate for all situations, and the most appropriate method of birth control depends on the woman's overall health, her age, the frequency of her sexual activity, her sexual partners, her desire to have children in the future, and personal or family history of certain diseases.

A special interest should be paid to women aged over 40 years. Decreased fertility, increased cardiovascular risks and greater exposure to gynecological disorders during perimenopause have led to reassess the contraceptive methods in this age group. Official guidelines allow the use of any contraceptive method - including combined estrogen progestin contraceptives (COCs) - that it had been well tolerated previously.

However, more frequent contraindications during perimenopause can lead women to switch to other methods, such as the intrauterine device, the progestin-only contraception or sterilization. In this context, local contraception with spermicides represents an attractive alternative for perimenopausal women. Being totally safe, particularly metabolically, the use of spermicides in this age group is not restricted by national and international guidelines except in HIV high risk women or women with HIV clinical disease.

Furthermore, the lubricating effect of a galenic formulation of spermicides, such as cream, is particularly useful in cases of vaginal dryness, which is common in perimenopausal women. Lastly, spermicides may be used in combination with other local methods of contraception. Considering the contraindications to other contraceptives, particularly hormonal contraceptives, and the greater risks associated with these methods during perimenopause, spermicides could be an appropriate alternative for a large number of perimenopausal women.

Today, in spite of many advantages of spermicides, there is no contraceptive efficacy study conducted with any spermicide in women aged over 40 years. That is why the aim of this study is to evaluate contraceptive efficacy, tolerance and acceptability of a spermicide with benzalkonium chloride (Pharmatex® cream) in women aged over 40 years.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 151
• Est. completion date: October 17, 2019
• Est. primary completion date: October 17, 2019
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 40 Years and older

Eligibility

Inclusion Criteria:

1. Women = 40 years of age, fertile, having had at least one menstrual cycle in the course of the last three months

2. Women who were informed about the risks and benefits of all contraceptive methods, and for whom contraceptive methods other than spermicides were not suitable

3. Women who need a contraceptive method and who accept to use a spermicide for at least 6 months.

4. Women who have a negative pregnancy test at inclusion (the urinary pregnancy test should be performed at investigator's office then confirmed by a blood test performed in a local laboratory (quantitative beta hCG dosage)).))

5. Women who accept to comply with the requirements of the protocol including visits assessments and diary completion after each sexual intercourse

6. Women who have had a normal smear test < 3 years

7. Women affiliated to a public health insurance coverage

8. Women who have read, understood, dated and signed the informed consent form

Exclusion Criteria:

1. Women who are not able to understand a birth control method with Pharmatex® cream

2. Women who have had an unprotected sexual intercourse within 7 days before the Baseline Visit

3. Allergy or hypersensitivity to one of the components of Pharmatex® cream

4. Medical contraindication to pregnancy

5. Abnormal results of cervico-vaginal and/or vulvo-vaginal clinical examination (e.g. severe atrophic vaginitis etc.)

6. Women with history of > 2 induced abortions during lifetime (miscarriages and spontaneous abortions are not included)

7. Women with history of infectious vaginitis within the last 6 months

8. Women treated for STI within the last three months

9. HIV positive women and high-risk women for HIV

10. Breastfeeding women

11. Women participating or having participated in a clinical trial within four weeks prior to inclusion

12. Women deprived of liberty by a legal or administrative decision

Related Conditions & MeSH terms

• Contraception

Intervention

Drug:
• Benzalkonium Chloride Spermicide Cream
One dose of Pharmatex vaginal cream (benzalkonium chloride) must be used systematically before each intercourse, regardless of the cycle period, even during menstrual periods. In case of repeated acts of intercourse, an additional dose of cream must be used before each new act. Duration of treatment : 6 months (12 months optional)

Locations

Country	Name	City	State
France	Cabinet Gynecologie	Carnoux-en-Provence
France	Cabinet de Gynecologie	Écully
France	Cabinet de Gynecologie	Lyon
France	Cabinet Gynecologie	Lyon
France	Cabinet de Gynecologie	Marseille
France	Cabinet de Gynecologie	Nantes
France	Cabinet Gynecologie	Neuilly-sur-Seine
France	Cabinet Gynecologie	Orléans
France	Cabinet Gynecologie	Paris
France	Cabinet Gynecologique	Strasbourg
Russian Federation	"The Pirogov Russian National Research Medical University"	Moscow
Russian Federation	A.I. Yevdokimov Moscow State University of Medicine and Dentistry"	Moscow
Russian Federation	Closed Joint-Stock Company "Heirs"/Nasledniki Ltd.	Moscow
Russian Federation	FSBI "Scientific Center of Obstetrics, Gynecology and Perinatology n.a. V.I. Kulakov"	Moscow
Russian Federation	I.M. Sechenov First Moscow State Medical University"	Moscow

Sponsors (2)

Lead Sponsor	Collaborator
Laboratoire Innotech International	ITEC Services

Countries where clinical trial is conducted

France,  Russian Federation, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Contraceptive Efficacy- PI over up to 12 months - typical use	Contraceptive efficacy of Pharmatex® cream expressed by the Pearl Index (PI) over up to 12 months of typical use. The Pearl Index is defined as the number of unintended pregnancies per 100 woman-years of a contraceptive method's use; Success: no fertilisation; Failure: unintended fertilisation (pregnancy or aborted pregnancy)	up to 12 months after the inclusion
Secondary	Contraceptive Efficacy - PI over up to 12 months - perfect use	Contraceptive efficacy of Pharmatex® cream expressed by the Pearl Index (PI) over up to 12 months of perfect use	up to 12 months after the inclusion
Secondary	Contraceptive Efficacy - PI over up to 6 months - typical use	Contraceptive efficacy of Pharmatex® cream expressed by the Pearl Index (PI) at Visit 3 (M6) over up to 6 months of typical use	up to 6 months after the inclusion
Secondary	Contraceptive Efficacy - PI over up to 6 months - perfect use	Contraceptive efficacy of Pharmatex® cream expressed by the Pearl Index (PI) at Visit 3 (M6) over up to 6 months of perfect use	up to 6 months after the inclusion
Secondary	Contraceptive Efficacy - Pregnancy rate over up to 6 months - typical use	Contraceptive efficacy of Pharmatex® cream expressed by the rate of pregnancy over up to 6 months of typical use at Visit 3 (M6)	up to 6 months after the inclusion
Secondary	Contraceptive Efficacy - Pregnancy rate over up to 6 months - perfect use	Contraceptive efficacy of Pharmatex® cream expressed by the rate of pregnancy over up to 6 months of perfect use at Visit 3 (M6)	up to 6 months after the inclusion
Secondary	Contraceptive Efficacy - Pregnancy rate over up to 12 months - typical use	Contraceptive efficacy of Pharmatex® cream expressed by the rate of pregnancy over up to 12 months of typical use at Visit 4 (M12)	up to 12 months after the inclusion
Secondary	Contraceptive Efficacy - Pregnancy rate over up to 12 months - perfect use	Contraceptive efficacy of Pharmatex® cream expressed by the rate of pregnancy over up to 12 months of perfect use at Visit 4 (M12)	up to 12 months after the inclusion
Secondary	Number of adverse events	Number of adverse events during the study	6 or 12 months after the inclusion
Secondary	Percentage of adverse events	Percentage of adverse events during the study	6 or 12 months after the inclusion
Secondary	Acceptability - percentage of continuation	Evaluation of the acceptability of the treatment by percentage of continuation until the end of follow-up (at 6 months for all the women and at 12 months for women who have accepted to continue at visit 3 (M6))	up to 6 or 12 months after the inclusion
Secondary	Acceptability - adherence	Evaluation of the acceptability of the treatment through adherence: systematic use of benzalkonium chloride spermicide before each event of sexual intercourse recorded in the self-evaluation diary	up to 6 or 12 months after the inclusion
Secondary	Acceptability - ease of use (Likert scale)	Evaluation of the acceptability of the treatment (ease of use) evaluated through the self-evaluation diary (Likert scale) up to M6 (V3) and up to M12 (V4) for women who have continued for 12 months	up to 6 or 12 months after the inclusion
Secondary	Acceptability - lubricating effect (Likert scale)	Evaluation of the acceptability of the treatment through the lubricating effect (Likert scale) at the end of study visit: V3 (M6), or V4 (M12) or at intermediate visit in case of early withdrawal	up to 6 or 12 months after the inclusion
Secondary	Acceptability - global satisfaction of the woman (Likert scale)	Evaluation of the global satisfaction of the treatment (Likert scale) by the woman at V2 (M2), V3 (M6) and V4 (M12) and during phone contacts PC1 (M1), PC2 (M4) and PC3 (M9)	1, 2, 4, 6, 9, 12 months after the inclusion
Secondary	Acceptability - global satisfaction of the investigator (Likert scale)	Evaluation of the global satisfaction of the treatment (Likert scale) by the investigator at V2 (M2), V3 (M6) and V4 (M12).	2, 6, 12 months after the inclusion